Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677988 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma
A Phase 2 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01677988 is a Phase 2 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 3 participants.
The verdict
NCT01677988, a Phase 2 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is for subjects with adenocarcinoma of the pancreas. The purpose of this research study is to determine the safety and effectiveness of modified Folfirinox and radiation therapy as treatment for adenocarcinoma (cancer) of the pancreas before surgery. Screening tests will be done to determine if subjects are eligible for participation in this study. If subjects are eligible to participate and agree to participate they will begin chemotherapy. After 3 cycles of chemotherapy, subjects will begin chemoradiation. Within 4 to 8 weeks of completing radiation therapy, subjects will have surgery. There will also be post-treatment and follow-up evaluations. Subjects will be followed for every 3 months for 3 years after their initial registration.
Interventions
- PROCEDURE Surgical Resection
- RADIATION Chemoradiation
- DRUG Neo-adjuvant Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677988
The ClinicalTrials.gov registry entry for NCT01677988 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Surgical Resection is the first listed.
NCT01677988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01677988 about?
NCT01677988 is a clinical study titled "Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma". This study is for subjects with adenocarcinoma of the pancreas. The purpose of this research study is to determine the safety and effectiveness of modified Folfirinox and radiation therapy as treatment for adenocarcinoma (cancer) of the pancreas before surgery. Screening tests will be done to determ...
What is the current status of trial NCT01677988?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2012-07.
What interventions are being tested in trial NCT01677988?
The interventions under investigation include: Surgical Resection (PROCEDURE), Chemoradiation (RADIATION), Neo-adjuvant Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT01677988?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.